Abstract:
This article reviews the renin-angiotensin system (RAS) and its central role in the development of left ventricular hypertrophy (LVH). It also presents an overview of the pharma ceutical blockades available and the clinical trial evidence for their ability to prevent the progression of LVH or induce its regression, thereby improving clinical outcome